← Back to Patent Explorer
US4228127A Expired / Lapsed US ⏱️ 0.0 years remaining

Kit for detecting human chorionic gonadotropin

Assignee: IMMUNOPATHOLOGY INSTITUTE Inc
•
Filing: 1978-10-06
•
Granted: 1980-10-14
•
Expires: 1998-10-06
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A diagnostic cell test and kit for detecting human chorionic gonadotropin as evidence of cancer. The subject's cells undergoing examination are contacted with antiserum specific to the beta-subunit of human chorionic gonadotropin, the antiserum having been raised in a host animal. The treated cells are divided into two portions. The portions are treated with antiserum to the gamma globulin of the host animal. The antiserum to the gamma globulin used in treating the first portion is conjugated to fluorescin, and the antiserum used in contacting the second portion is conjugated to peroxidase. A positive test for cancer is concluded only when both tests on the two portions of the cells are positive.

Inventors

  • 👤 Hernan F. Acevedo
  • 👤 Malcolm Slifkin
  • 👤 Milton H. Dalbow

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-08 15:20
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/74; G01N33/76; Y; Y10; Y10S; Y10S436/00; Y10S436/80; Y10S436/807; Y10S436/808; Y10S436/815; Y10S436/817; Y10S436/818

Claims Analysis

Total Claims: 2
Claim 1
Independent Claim 289 words
A diagnostic test kit for detecting the absence or the presence of suspected malignant neoplastic cells in a cell specimen by testing for human chorionic gonadotropin, said diagnostic cell test kit comprising: (a) antiserum specific to the beta-subunit of human chorionic gonadotropin, said beta-subunit having been raised in a host animal, for treating cell samples to be tested, followed by rinsing to remove any excess antiserum; (b) antiserum specific to gamma globulin of said host animal conjugated to fluorescein for adding to a portion of said sample to be tested which has been treated with said beta-subunit of human chorionic gonadotropin followed by examination of said portion with an ultraviolet microscope which passes the ultraviolet light through said cells; if fluorescein is found, the indirect fluorescein-labelled antibody test is considered positive; if no staining is found, this indirect test is considered negative; and (c) antiserum specific to said gamma globulin of said host animal conjugated to peroxidase for adding to a second portion of said cell specimen treated with said antiserum specific to the beta-subunit of human chorionic gonadotropin and peroxidase activator, added to said second cell sample followed by an examination of said second portion with a microscope to determine whether peroxidase staining has occurred, the indirect peroxidase-labelled antibody test is considered positive if staining is found; if no staining is found, the test is negative; the cell test for human chorionic gonadotropin is then considered positive only if both indirect labelled antibody tests are positive; if both indirect antibody tests are negative or if one indirect labelled antibody test is positive and the other is negative, the diagnostic cell test is negative for human chorionic gonadotropin, establishing that neoplastic cells are not present in the cells tested.
Claim 2
Dependent Claim 289 words
A diagnostic test kit for detecting the absence or the presence of suspected malignant neoplastic cells in a cell specimen by testing for human chorionic gonadotropin, said diagnostic cell test kit comprising: (a) antiserum specific to the beta-subunit of human chorionic gonadotropin, said beta-subunit having been raised in a host animal, for treating cell samples to be tested, followed by rinsing to remove any excess antiserum; (b) antiserum specific to gamma globulin of said host animal conjugated to fluorescein for adding to a portion of said sample to be tested which has been treated with said beta-subunit of human chorionic gonadotropin followed by examination of said portion with an ultraviolet microscope which passes the ultraviolet light through said cells; if fluorescein is found, the indirect fluorescein-labelled antibody test is considered positive; if no staining is found, this indirect test is considered negative; and (c) antiserum specific to said gamma globulin of said host animal conjugated to peroxidase for adding to a second portion of said cell specimen treated with said antiserum specific to the beta-subunit of human chorionic gonadotropin and peroxidase activator, added to said second cell sample followed by an examination of said second portion with a microscope to determine whether peroxidase staining has occurred, the indirect peroxidase-labelled antibody test is considered positive if staining is found; if no staining is found, the test is negative; the cell test for human chorionic gonadotropin is then considered positive only if both indirect labelled antibody tests are positive; if both indirect antibody tests are negative or if one indirect labelled antibody test is positive and the other is negative, the diagnostic cell test is negative for human chorionic gonadotropin, establishing that neoplastic cells are not present in the cells tested.

References Cited (Backward Citations)

US3720760A Cited
US3720760B1 Cited
US3654090A Cited
US3654090B1 Cited
US3873683A Cited
US3697638A Cited
US3789116A Cited
US3901654A Cited
US3868219A Cited
US3992514A Cited
US3935074A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1983-10-14 1984-04-14 1984-10-14 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1987-10-14 1988-04-14 1988-10-14 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1991-10-14 1992-04-14 1992-10-14 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag